Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other financing activities (2020 - 2021)

Barinthus Biotherapeutics' Other financing activities history spans 2 years, with the latest figure at $1.4 million for Q3 2021.

  • For Q3 2021, Other financing activities changed N/A year-over-year to $1.4 million; the TTM value through Dec 2021 reached $2.2 million, changed N/A, while the annual FY2021 figure was $2.2 million, 3698.25% up from the prior year.
  • Other financing activities reached $1.4 million in Q3 2021 per BRNS's latest filing, up from $756000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.4 million in Q3 2021 to a low of $22000.0 in Q1 2021.